Monday - May 12, 2025

LOGIN  |  REGISTER
Astria Therapeutics

PACS Group to Announce First Quarter 2024 Financial Results

May 06, 2024 | Last Trade: US$10.43 0.17 -1.60

FARMINGTON, Utah / May 06, 2024 / Business Wire / PACS Group, Inc. (NYSE: PACS) (“PACS Group” or the “Company”), today announced that it will release its first quarter 2024 financial results after market close on Monday, May 13, 2024. Management will host a call the following day, Tuesday, May 14, 2024, at 4:00 p.m. Eastern Time to discuss the financial results and related information.

PACS Group invites current and prospective investors to listen to the call via webcast by going to the Investors section of the PACS Group website at https://IR.pacs.com. A recording of the call will be available for replay via the website for 30 days following the call. The Company’s press releases, SEC filings, public conference calls, webcasts and website frequently disclose information that may be material to investors, and the Company encourages investors and others interested in the Company to regularly monitor those outlets for important Company information.

About PACS Group

PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate over 200 post-acute care facilities across nine states serving over 22,000 patients daily.

Viking Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page